Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.37 -0.13 (-0.72%)

Delayed Quote Updated: 2:11 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

36 37 Next >

Insiders Are Buying These 2 Stocks

September 08, 2023

Insider buying in both Loews (NYSE: L) and Sarepta (NASDAQ: SRPT) suggests a positive outlook for these stocks, potentially influencing investor sentiment.

Via MarketBeat

Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year

September 07, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 05, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 31, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Is Sarepta Therapeutics Stock a Top Growth Vehicle? ↗

August 23, 2023

An upcoming data readout could fuel another rally in the biotech's shares.

Via The Motley Fool

Analyst Ratings for Sarepta Therapeutics ↗

August 03, 2023

Via Benzinga

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

August 22, 2023

Helping save and improve patients' lives in novel ways can be a lucrative activity.

Via The Motley Fool

Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

August 15, 2023

Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades.

Via Benzinga

$3M Bet On Tidewater? Check Out These 4 Stocks Insiders Are Buying ↗

August 14, 2023

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

Via Benzinga

Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript ↗

August 02, 2023

SRPT earnings call for the period ending June 30, 2023.

Via The Motley Fool

Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments

August 02, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Earnings Preview: Sarepta Therapeutics ↗

August 01, 2023

Via Benzinga

2 Biotech Growth Stocks I'd Buy Right Now ↗

July 27, 2023

Both drugmakers seem to have a bright future ahead.

Via The Motley Fool

Where Sarepta Therapeutics Stands With Analysts ↗

July 14, 2023

Via Benzinga

What 25 Analyst Ratings Have To Say About Sarepta Therapeutics ↗

June 23, 2023

Via Benzinga

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results

July 26, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

3 Biotech Stocks to Sell Before They Damage Your Portfolio ↗

July 12, 2023

With the Street generally bearish towards the biotech sector, investors need to identify biotech stocks to avoid at this point.

Via InvestorPlace

Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million

July 05, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Wins FDA Approval For Highly Anticipated Gene Therapy ↗

June 22, 2023

Sarepta will sell the Duchenne muscular dystrophy gene therapy under the brand name Elevidys.

Via Investor's Business Daily

Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit

July 03, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 30, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%? ↗

June 30, 2023

While its gene therapy for Duchenne muscular dystrophy has been conditionally approved, it'll take a while to prove its merit.

Via The Motley Fool

Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)

June 27, 2023

Recent events surrounding Sarepta Therapeutics highlights the unpredictability of the biotech industry and its appropriateness solely for high-risk investors.

Via MarketBeat

Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 23, 2023

Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023 ↗

June 23, 2023

Via Benzinga

Canopy Growth, Avadel Pharmaceuticals And Other Big Stocks Moving Lower On Friday ↗

June 23, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. GSR II Meteora Acquisition Corp. (NASDAQ: GSRM)...

Via Benzinga

Sarepta Therapeutics' Therapy Becomes First To Score FDA Nod For Duchenne Muscular Dystrophy Gene Therapy ↗

June 22, 2023

The FDA has granted accelerated approval to closely watched Sarepta Therapeutics Inc's (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged...

Via Benzinga

Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy

June 22, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence ↗

June 20, 2023

Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a

Via Benzinga

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.